NCT01975831 - A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab | Biotech Hunter

Enrollment

104

Participants

Timeline

Start Date

December 19, 2013

Primary Completion Date

December 31, 2019

Study Completion Date

July 2, 2021

Conditions

Breast CancerOvarian CancerColorectal CancerCervical CancerRenal Cell Carcinoma

Interventions

DRUG

Durvalumab

Durvalumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.

DRUG

Tremelimumab

Tremelimumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.

Trial Locations (6)

Memorial Sloan Kettering Cancer Center, New York

Roswell Park Cancer Institute, Buffalo

University of Virginia Division of Hematology and Oncology, Charlottesville

Mary Crowley Cancer Research Center, Dallas

Yale Cancer Center, New Haven

Dana-Farber Cancer Institute, Boston